Everything I learned building a biotech's global hiring infrastructure

In mid-2024, Outlook Therapeutics was a pre-commercial biotech at an inflection point. LYTENAVA™ had just received regulatory approval in the EU and U.K. as a treatment for wet age-related macular degeneration, a leading cause of vision loss.